Get the Stockscreener App
151.58
1.88%
-2.69
Biogen Inc stock is traded at $151.58, with a volume of 1.05M.
It is down -1.88% in the last 24 hours and down -5.32% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$154.27
Open:
$153.6
24h Volume:
1.05M
Relative Volume:
0.65
Market Cap:
$22.22B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
14.50
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
+0.62%
1M Performance:
-5.32%
6M Performance:
+22.53%
1Y Performance:
-12.90%
1-Day Range:
$149.63
$155.33
1-Week Range:
$138.00
$155.33
52-Week Range:
$110.03
$179.20
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
151.53 | 22.63B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
898.38 | 772.28B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
186.32 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
212.32 | 385.18B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.21 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.05 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
BIIB: Bernstein Raises Price Target for Biogen to $157 with Mark - GuruFocus
Biogen to present felzartamab data at Kidney Week 2025 - Investing.com
Biogen (BIIB) Reveals New Data on Felzartamab at Kidney Week 202 - GuruFocus
Why Biogen Inc. (IDP) stock stays on top picksJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
Biogen Inc. to Present Groundbreaking Longitudinal Gene Expression Data on Felzartamab at Kidney Week 2025 - Quiver Quantitative
Biogen Inc. $BIIB Shares Bought by State of Michigan Retirement System - MarketBeat
Plato Investment Management Ltd Raises Stock Holdings in Biogen Inc. $BIIB - MarketBeat
FY2025 EPS Estimates for Biogen Decreased by Leerink Partnrs - MarketBeat
Should you wait for a breakout in Biogen Inc.2025 Key Lessons & Smart Money Movement Tracker - newser.com
How to escape a deep drawdown in Biogen Inc.Portfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Amgen Earnings: What To Look For From AMGN - FinancialContent
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Guggenheim Increases Biogen (NASDAQ:BIIB) Price Target to $185.00 - MarketBeat
Biogen (NASDAQ:BIIB) Given New $150.00 Price Target at BMO Capital Markets - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Raised to $143.00 - MarketBeat
Biotech Investments Market Seeking Excellent Growth | Biogen (US), Moderna, Johnson & Johnson - openPR.com
How a Strong Q3 and Increased R&D Spending at Biogen (BIIB) Has Changed Its Investment Story - simplywall.st
Biogen shares drop as full-year guidance cut outweighs strong Q3 results - MSN
Savvy Advisors Inc. Buys New Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stock Holdings Increased by Wealthfront Advisers LLC - MarketBeat
Biogen (NASDAQ:BIIB) Stock Rating Lowered by Wall Street Zen - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Q3 2025 Earnings Call Transcript - Insider Monkey
Biogen’s Earnings Call Highlights Robust Growth and Positive Outlook - The Globe and Mail
Key metrics from Biogen Inc.’s quarterly dataWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Institutional scanner results for Biogen Inc.Options Play & Free Community Supported Trade Ideas - newser.com
Royal Bank Of Canada Lowers Biogen (NASDAQ:BIIB) Price Target to $210.00 - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Cut to $250.00 by Analysts at Robert W. Baird - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Option Care Health (OPCH) and Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Biogen outlines 67% launch product growth and signals expanded pipeline momentum amid strong Q3 results - MSN
Sector ETF performance correlation with Biogen Inc.Trade Analysis Report & Consistent Profit Focused Trading Strategies - newser.com
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $3.44 Million Stake in Biogen Inc. $BIIB - MarketBeat
Analyzing Biogen Inc. with multi timeframe chartsTrade Volume Summary & Long-Term Growth Plans - newser.com
Is Biogen Inc. stock a top momentum playWeekly Trend Recap & Reliable Intraday Trade Plans - newser.com
Biogen Inc. Reports Strong Q3 2025 Results - The Globe and Mail
Biogen (NASDAQ:BIIB) Issues Earnings Results - MarketBeat
BMO Capital Adjusts Biogen Price Target to $150 From $128 - MarketScreener
Biogen (BIIB) Rating Maintained as RBC Capital Lowers Price Targ - GuruFocus
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands - Yahoo Finance
Wedbush Raises Price Target on Biogen to $143 From $135, Keeps Neutral Rating - MarketScreener
Wells Fargo Adjusts Price Target on Biogen to $155 From $140 - MarketScreener
Baird Adjusts Price Target on Biogen to $250 From $255 - MarketScreener
Biogen (NASDAQ:BIIB) Issues FY 2025 Earnings Guidance - MarketBeat
Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative - Yahoo Finance
RBC Cuts Price Target on Biogen to $210 From $217, Keeps Outperform Rating - MarketScreener
Volatility clustering patterns for Biogen Inc.Market Activity Summary & Fast Gain Swing Alerts - newser.com
Emerald Advisers LLC Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Lowers Outlook Even As Profits And Sales Top Estimates - Finimize
How Biogen Inc. (IDP) stock behaves in tightening cyclesStock Surge & Low Risk High Reward Trade Ideas - newser.com
When is the best time to exit Biogen Inc.July 2025 Volume & Free Community Supported Trade Ideas - newser.com
Biogen stock price target raised to $185 from $165 at Guggenheim - Investing.com
Biogen Inc (BIIB) Q3 Earnings: EPS of $3.17 Beats Estimates, Rev - GuruFocus
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):